Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 2/20 | 0.71 |
| ▸ | TMPRSS4 | Q9NRS4 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | PLAU | P00749 | 4/20 | 0.54 |
| ▸ | F2 | P00734 | 2/20 | 0.54 |
| ▸ | F10 | P00742 | 2/20 | 0.54 |
| ▸ | PLAT | P00750 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL134080 | 0.88 | TMPRSS4 (0.77) | P2RX1TMPRSS4MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL330294 | 0.82 | TMPRSS4 (0.58) | P2RX1TMPRSS4MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL28187514 | 0.82 | RAB9A (0.52) | P2RX1MAPTALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL330991 | 0.81 | TMPRSS4 (0.68) | P2RX1TMPRSS4MAPTALDH1A1SMN1; SMN2 | |
| Dibromsalan SCHEMBL29496335 | 0.80 | PLAU (0.73) | P2RX1TMPRSS4MAPTALDH1A1SMN1; SMN2 | |
| Dibromsalan SCHEMBL646973 | 0.80 | PLAU (0.73) | P2RX1TMPRSS4MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL28187513 | 0.80 | ALDH1A1 (0.50) | P2RX1MAPTALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL28187530 | 0.80 | RAB9A (0.50) | P2RX1MAPTALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL12218147 | 0.79 | RAB9A (0.79) | ALDH1A1SMN1; SMN2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL25349138 | 0.79 | TMPRSS4 (0.64) | P2RX1TMPRSS4MAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263657-B2 | Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8097759-B2 | Inflammatory cytokine release inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-10-09 | — | — | US | disclosed |
| EP-1847263-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-24 | — | — | EP | disclosed |
| EP-1844766-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | P2RX1 1459/4885TMPRSS4 1813/4885MAPT 1849/4885 |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | P2RX1 1538/4885TMPRSS4 1647/4885MAPT 2086/4885 |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | P2RX1 1538/4885TMPRSS4 1647/4885MAPT 2086/4885 |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | NFKBIA, IL1B, IKBKB | P2RX1 2316/4885TMPRSS4 3292/4885MAPT 2435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.